Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Aspirin cuts risk of bowel cancer death by third

  • Comment

Aspirin can reduce the chances of dying from bowel cancer by almost a third, research has shown.

Patients who took a daily dose of the pain killer for at least nine months after being diagnosed cut the likelihood of the disease killing them by 30%.

Taking aspirin for any length of time after diagnosis reduced the odds of dying from cancer by 23% compared with not taking aspirin at all.

The study looked at 4,500 bowel cancer patients in the Netherlands diagnosed between 1998 and 2007.

A quarter were not aspirin users, another quarter only took aspirin after diagnosis, while the remaining group took it both before and after developing cancer.

Lead researcher Dr Gerrit-Jan Liefers, from Leiden University Medical Centre in the Netherlands, said: “Our findings could have profound clinical implications. In this study, we showed the therapeutic effect of a widely-available, familiar drug that costs mere pennies per day.

“It’s possible that some older people may have other health problems which mean that they are not well enough to have chemotherapy. Bowel cancer is more common in older people so these results could be a big advance in treatment of the disease, particularly in this group. But we need further research to confirm this.”

His team is now planning a randomised controlled trial due to start later this year which will target the over-70s population.

The results are published today in the British Journal of Cancer, owned by Cancer Research UK.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.